The global PD-L1 Biomarker Testing market size is predicted to grow from US$ 2754 million in 2025 to US$ 20870 million in 2031; it is expected to grow at a CAGR of 40.1% from 2025 to 2031.
PD-L1 Biomarker Testing measures the amount of PDL1 on cancer cells. PDL1 is a protein that helps keep immune cells from attacking nonharmful cells in the body. Normally, the immune system fights foreign substances like viruses and bacteria, and not your own healthy cells. Some cancer cells have high amounts of PDL1. This allows the cancer cells to "trick" the immune system, and avoid being attacked as foreign, harmful substances.
Current PD-L1 testing is based on immunohistochemistry (IHC) methods. Immunohistochemistry (IHC) is the process whereby antibodies are used to detect proteins (antigens) in cells within a tissue section (for instance liver, pancreas or the heart).
PD-L1 is a ligand that binds to PD-1 (programmed cell death-1), expressed on activated T cells, to evade anti-tumor responses. PD-L1 plays a role in inhibiting T cell activation and proliferation and has emerged as an important target in cancer treatment. PD-L1 protein detection by immunohistochemistry (IHC) testing is widely used as a predictive biomarker assay for anti鈥揚D-1/PD-L1 therapies.
PDL1 testing is used to find out if you have a cancer that may benefit from immunotherapy.
The classification of PD-L1 Biomarker Testing includes PD-L1 (22C3), PD-L1 (28-8), PD-L1 (SP142), PD-L1 (SP263) and Other, and the revenue proportion of PD-L1 (22C3) in 2019 is about 21.68%.
PD-L1 Biomarker Testing is widely used in Hospital and Diagnostic Laboratories. The most proportion of PD-L1 Biomarker Testing is Hospital, and the proportion in 2019 is about 52.7%.
North Americas is the largest consumption place, with a consumption market share nearly 55.63% in 2019. Following North Americas, Europe is the second largest consumption place with the consumption market share of 26.7%.
The 鈥淧D-L1 Biomarker Testing Industry Forecast鈥� looks at past sales and reviews total world PD-L1 Biomarker Testing sales in 2024, providing a comprehensive analysis by region and market sector of projected PD-L1 Biomarker Testing sales for 2025 through 2031. With PD-L1 Biomarker Testing sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world PD-L1 Biomarker Testing industry.
This Insight Report provides a comprehensive analysis of the global PD-L1 Biomarker Testing landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on PD-L1 Biomarker Testing portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms鈥� unique position in an accelerating global PD-L1 Biomarker Testing market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for PD-L1 Biomarker Testing and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global PD-L1 Biomarker Testing.
This report presents a comprehensive overview, market shares, and growth opportunities of PD-L1 Biomarker Testing market by product type, application, key players and key regions and countries.
Segmentation by Type:
PD-L1 (22C3)
PD-L1(28-8)
PD-L1 (SP142)
PD-L1 (SP263)
Other
Segmentation by Application:
Hospital
Diagnostic Center
Others
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Agilent Technologies
Roche
Merck
Bristol-Myers Squibb
AstraZeneca
Ono Pharmaceutical
Regeneron
Innovent
Hengrui Medicine
Junshi Biosciences
Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.
1 Scope of the Report
1.1 麻豆原创 Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 麻豆原创 Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 麻豆原创 Estimation Caveats
2 Executive Summary
2.1 World 麻豆原创 Overview
2.1.1 Global PD-L1 Biomarker Testing 麻豆原创 Size (2020-2031)
2.1.2 PD-L1 Biomarker Testing 麻豆原创 Size CAGR by Region (2020 VS 2024 VS 2031)
2.1.3 World Current & Future Analysis for PD-L1 Biomarker Testing by Country/Region (2020, 2024 & 2031)
2.2 PD-L1 Biomarker Testing Segment by Type
2.2.1 PD-L1 (22C3)
2.2.2 PD-L1(28-8)
2.2.3 PD-L1 (SP142)
2.2.4 PD-L1 (SP263)
2.2.5 Other
2.3 PD-L1 Biomarker Testing 麻豆原创 Size by Type
2.3.1 PD-L1 Biomarker Testing 麻豆原创 Size CAGR by Type (2020 VS 2024 VS 2031)
2.3.2 Global PD-L1 Biomarker Testing 麻豆原创 Size 麻豆原创 Share by Type (2020-2025)
2.4 PD-L1 Biomarker Testing Segment by Application
2.4.1 Hospital
2.4.2 Diagnostic Center
2.4.3 Others
2.5 PD-L1 Biomarker Testing 麻豆原创 Size by Application
2.5.1 PD-L1 Biomarker Testing 麻豆原创 Size CAGR by Application (2020 VS 2024 VS 2031)
2.5.2 Global PD-L1 Biomarker Testing 麻豆原创 Size 麻豆原创 Share by Application (2020-2025)
3 PD-L1 Biomarker Testing 麻豆原创 Size by Player
3.1 PD-L1 Biomarker Testing 麻豆原创 Size 麻豆原创 Share by Player
3.1.1 Global PD-L1 Biomarker Testing Revenue by Player (2020-2025)
3.1.2 Global PD-L1 Biomarker Testing Revenue 麻豆原创 Share by Player (2020-2025)
3.2 Global PD-L1 Biomarker Testing Key Players Head office and Products Offered
3.3 麻豆原创 Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 PD-L1 Biomarker Testing by Region
4.1 PD-L1 Biomarker Testing 麻豆原创 Size by Region (2020-2025)
4.2 Global PD-L1 Biomarker Testing Annual Revenue by Country/Region (2020-2025)
4.3 Americas PD-L1 Biomarker Testing 麻豆原创 Size Growth (2020-2025)
4.4 APAC PD-L1 Biomarker Testing 麻豆原创 Size Growth (2020-2025)
4.5 Europe PD-L1 Biomarker Testing 麻豆原创 Size Growth (2020-2025)
4.6 Middle East & Africa PD-L1 Biomarker Testing 麻豆原创 Size Growth (2020-2025)
5 Americas
5.1 Americas PD-L1 Biomarker Testing 麻豆原创 Size by Country (2020-2025)
5.2 Americas PD-L1 Biomarker Testing 麻豆原创 Size by Type (2020-2025)
5.3 Americas PD-L1 Biomarker Testing 麻豆原创 Size by Application (2020-2025)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC PD-L1 Biomarker Testing 麻豆原创 Size by Region (2020-2025)
6.2 APAC PD-L1 Biomarker Testing 麻豆原创 Size by Type (2020-2025)
6.3 APAC PD-L1 Biomarker Testing 麻豆原创 Size by Application (2020-2025)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 Europe
7.1 Europe PD-L1 Biomarker Testing 麻豆原创 Size by Country (2020-2025)
7.2 Europe PD-L1 Biomarker Testing 麻豆原创 Size by Type (2020-2025)
7.3 Europe PD-L1 Biomarker Testing 麻豆原创 Size by Application (2020-2025)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa PD-L1 Biomarker Testing by Region (2020-2025)
8.2 Middle East & Africa PD-L1 Biomarker Testing 麻豆原创 Size by Type (2020-2025)
8.3 Middle East & Africa PD-L1 Biomarker Testing 麻豆原创 Size by Application (2020-2025)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 麻豆原创 Drivers, Challenges and Trends
9.1 麻豆原创 Drivers & Growth Opportunities
9.2 麻豆原创 Challenges & Risks
9.3 Industry Trends
10 Global PD-L1 Biomarker Testing 麻豆原创 Forecast
10.1 Global PD-L1 Biomarker Testing Forecast by Region (2026-2031)
10.1.1 Global PD-L1 Biomarker Testing Forecast by Region (2026-2031)
10.1.2 Americas PD-L1 Biomarker Testing Forecast
10.1.3 APAC PD-L1 Biomarker Testing Forecast
10.1.4 Europe PD-L1 Biomarker Testing Forecast
10.1.5 Middle East & Africa PD-L1 Biomarker Testing Forecast
10.2 Americas PD-L1 Biomarker Testing Forecast by Country (2026-2031)
10.2.1 United States 麻豆原创 PD-L1 Biomarker Testing Forecast
10.2.2 Canada 麻豆原创 PD-L1 Biomarker Testing Forecast
10.2.3 Mexico 麻豆原创 PD-L1 Biomarker Testing Forecast
10.2.4 Brazil 麻豆原创 PD-L1 Biomarker Testing Forecast
10.3 APAC PD-L1 Biomarker Testing Forecast by Region (2026-2031)
10.3.1 China PD-L1 Biomarker Testing 麻豆原创 Forecast
10.3.2 Japan 麻豆原创 PD-L1 Biomarker Testing Forecast
10.3.3 Korea 麻豆原创 PD-L1 Biomarker Testing Forecast
10.3.4 Southeast Asia 麻豆原创 PD-L1 Biomarker Testing Forecast
10.3.5 India 麻豆原创 PD-L1 Biomarker Testing Forecast
10.3.6 Australia 麻豆原创 PD-L1 Biomarker Testing Forecast
10.4 Europe PD-L1 Biomarker Testing Forecast by Country (2026-2031)
10.4.1 Germany 麻豆原创 PD-L1 Biomarker Testing Forecast
10.4.2 France 麻豆原创 PD-L1 Biomarker Testing Forecast
10.4.3 UK 麻豆原创 PD-L1 Biomarker Testing Forecast
10.4.4 Italy 麻豆原创 PD-L1 Biomarker Testing Forecast
10.4.5 Russia 麻豆原创 PD-L1 Biomarker Testing Forecast
10.5 Middle East & Africa PD-L1 Biomarker Testing Forecast by Region (2026-2031)
10.5.1 Egypt 麻豆原创 PD-L1 Biomarker Testing Forecast
10.5.2 South Africa 麻豆原创 PD-L1 Biomarker Testing Forecast
10.5.3 Israel 麻豆原创 PD-L1 Biomarker Testing Forecast
10.5.4 Turkey 麻豆原创 PD-L1 Biomarker Testing Forecast
10.6 Global PD-L1 Biomarker Testing Forecast by Type (2026-2031)
10.7 Global PD-L1 Biomarker Testing Forecast by Application (2026-2031)
10.7.1 GCC Countries 麻豆原创 PD-L1 Biomarker Testing Forecast
11 Key Players Analysis
11.1 Agilent Technologies
11.1.1 Agilent Technologies Company Information
11.1.2 Agilent Technologies PD-L1 Biomarker Testing Product Offered
11.1.3 Agilent Technologies PD-L1 Biomarker Testing Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.1.4 Agilent Technologies Main Business Overview
11.1.5 Agilent Technologies Latest Developments
11.2 Roche
11.2.1 Roche Company Information
11.2.2 Roche PD-L1 Biomarker Testing Product Offered
11.2.3 Roche PD-L1 Biomarker Testing Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.2.4 Roche Main Business Overview
11.2.5 Roche Latest Developments
11.3 Merck
11.3.1 Merck Company Information
11.3.2 Merck PD-L1 Biomarker Testing Product Offered
11.3.3 Merck PD-L1 Biomarker Testing Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.3.4 Merck Main Business Overview
11.3.5 Merck Latest Developments
11.4 Bristol-Myers Squibb
11.4.1 Bristol-Myers Squibb Company Information
11.4.2 Bristol-Myers Squibb PD-L1 Biomarker Testing Product Offered
11.4.3 Bristol-Myers Squibb PD-L1 Biomarker Testing Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.4.4 Bristol-Myers Squibb Main Business Overview
11.4.5 Bristol-Myers Squibb Latest Developments
11.5 AstraZeneca
11.5.1 AstraZeneca Company Information
11.5.2 AstraZeneca PD-L1 Biomarker Testing Product Offered
11.5.3 AstraZeneca PD-L1 Biomarker Testing Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.5.4 AstraZeneca Main Business Overview
11.5.5 AstraZeneca Latest Developments
11.6 Ono Pharmaceutical
11.6.1 Ono Pharmaceutical Company Information
11.6.2 Ono Pharmaceutical PD-L1 Biomarker Testing Product Offered
11.6.3 Ono Pharmaceutical PD-L1 Biomarker Testing Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.6.4 Ono Pharmaceutical Main Business Overview
11.6.5 Ono Pharmaceutical Latest Developments
11.7 Regeneron
11.7.1 Regeneron Company Information
11.7.2 Regeneron PD-L1 Biomarker Testing Product Offered
11.7.3 Regeneron PD-L1 Biomarker Testing Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.7.4 Regeneron Main Business Overview
11.7.5 Regeneron Latest Developments
11.8 Innovent
11.8.1 Innovent Company Information
11.8.2 Innovent PD-L1 Biomarker Testing Product Offered
11.8.3 Innovent PD-L1 Biomarker Testing Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.8.4 Innovent Main Business Overview
11.8.5 Innovent Latest Developments
11.9 Hengrui Medicine
11.9.1 Hengrui Medicine Company Information
11.9.2 Hengrui Medicine PD-L1 Biomarker Testing Product Offered
11.9.3 Hengrui Medicine PD-L1 Biomarker Testing Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.9.4 Hengrui Medicine Main Business Overview
11.9.5 Hengrui Medicine Latest Developments
11.10 Junshi Biosciences
11.10.1 Junshi Biosciences Company Information
11.10.2 Junshi Biosciences PD-L1 Biomarker Testing Product Offered
11.10.3 Junshi Biosciences PD-L1 Biomarker Testing Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.10.4 Junshi Biosciences Main Business Overview
11.10.5 Junshi Biosciences Latest Developments
12 Research Findings and Conclusion
听
听
*If Applicable.
